Niclosamide and Cancer: What the Research Shows

Niclosamide and Cancer: What the Research Shows

Niclosamide is an anthelmintic drug originally developed to treat tapeworm infections. Over the past two decades, researchers have investigated whether it might have anticancer properties. The scientific literature contains preclinical studies spanning multiple cancer types, but niclosamide is not an approved cancer treatment. Understanding what has been found in the lab and what remains uncertain helps separate established science from early-stage speculation.

How Niclosamide May Affect Cancer Cells

Laboratory studies suggest niclosamide could interfere with cancer cell growth through several mechanisms. Research indicates it may disrupt mitochondrial function, inhibit Wnt/β-catenin signaling, block mTOR pathways, and promote apoptosis in certain cancer cell lines. Some studies also point to anti-angiogenic effects, potentially limiting the blood supply tumors need to grow. These mechanisms have been observed in vitro and in animal models, but their relevance in humans remains under investigation.

Cancer Types Studied in Preclinical Research

Niclosamide has been tested in preclinical models against a range of cancers, including colorectal cancer, breast cancer, prostate cancer, lung cancer, glioblastoma, and hepatocellular carcinoma. In many of these studies, niclosamide showed the ability to reduce tumor cell viability or slow tumor growth in mice. The breadth of these findings has generated interest, but results vary widely depending on the cancer type, dosage, and experimental model. A finding in a petri dish or mouse model does not automatically translate to clinical benefit.

Clinical Trials and Human Data

As of current knowledge, niclosamide has not completed large-scale clinical trials proving its efficacy as a cancer treatment in humans. Some early-phase or exploratory studies may exist, but no phase III trials have established niclosamide as a standard oncological therapy. Researchers have explored repurposing the drug because its safety profile in humans is already known from decades of use as a dewormer, which could potentially accelerate the path to clinical application if efficacy is confirmed.

Why Niclosamide Is Not Yet an Approved Cancer Drug

Drug repurposing faces hurdles even when a compound has a known safety record. The gap between preclinical promise and clinical proof requires rigorous human trials that assess dosing, bioavailability, tumor-specific activity, and side effects in cancer patients. Niclosamide's solubility and pharmacokinetics also present formulation challenges that researchers are working to address. Until those hurdles are cleared through controlled trials, niclosamide remains an experimental compound in oncology, not a standard treatment option.

Current Status and What Patients Should Know

Niclosamide is available as a prescription medication for parasitic infections in many countries. It is not approved by major regulatory agencies for cancer treatment. Patients considering any off-label use should discuss the risks and lack of proven benefit with an oncologist. Participating in clinical trials may be an option for some individuals, and trial registries can provide current information on studies involving niclosamide and cancer.

Ongoing Research Directions

Scientists continue to study niclosamide's potential in combination therapies, nanoparticle formulations to improve delivery, and biomarkers that might predict which patients could benefit most. Research is also examining whether niclosamide could sensitize resistant tumors to conventional treatments. These efforts represent the standard drug development process, and results will determine whether niclosamide moves closer to becoming a recognized tool in cancer care.